Global Acromegaly Treatment Market By Product (GHRA, Somatostatin analogs and Other Products), By End-Use (Hospitals & clinics and Other End-Uses), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Acromegaly Treatment Market Overview:

Global acromegaly treatment market was valued at USD 1,497 million in 2021. It is forecast to grow 7.55% over the forecast period.

The increasing incidence of the disease has led to high demand for advanced treatment options, which in turn have boosted the development of newer molecules. Pharmaceutical companies invest in R&D to develop new formulations and new routes of administration for existing drugs.

Global Acromegaly Treatment Market Analysis:

Product Analysis

Over the last few decades, the first-line treatment option for somatostatin analogues has been recommended by healthcare professionals. This is due to the availability of drugs and the cost-efficiency. In 2021, the somatostatin analogues segment accounted for the largest revenue share. There are three marketed drugs: Sandostatin, Signifor, and Somatuline Depot from Ipsen Pharma.

A strong pipeline of drugs will also be a key driver for future growth. Somatuline Autogel from Ipsen Pharma, CRN00808 of Crinetics Pharmaceuticals and MYCAPSSA oral, Chiasma Inc. are all currently in clinical trials. They should be approved within the next few years.

Pfizer Inc. currently offers Somavert (Pegvisomant), which is the only Growth Hormone Receptor Antagonist. Two GHRIs currently in development are ISIS 766720 and Ionis Pharmaceuticals Inc., which is currently undergoing phase II clinical trials.

End-Use Analysis

Hospitals and clinics accounted for held significant revenue share in 2021. This is due to a large number of surgeries and diagnostic procedures performed in these facilities. Its largest market share is also due to the availability of surgeons and advanced diagnostics equipment. However, the lack of knowledge and late detection could limit the growth in the future.

Other segments include government and private organizations. A research study was done in China’s government hospital. 527 patients with the acromegalic disease were identified using facial photos and machine learning. This initiative encouraged early detection of the disease in the population.

Key Market Segments:

By Product

• GHRA
• Somatostatin analogs
• Other Products

By End-Use

• Hospitals & clinics
• Other End-Uses

Market Dynamics:

In the coming years, rising demand will be a result of the increasing prevalence of genetic diseases and lifestyle changes. The growth is expected to be supported by an increase in the incidence of hormone diseases such as hypopituitarism, endocrine disorders, and hypopituitarism. Market players will benefit from technological advancements and government support.

The key driver of the acromegaly market is a strong drug pipeline. Seven somatostatin analogues and two growth hormone receptor antagonists will be approved by the FDA by 2032. This market will also benefit from technological advancements such as radiosurgery and radiolabelled imaging technologies that provide cost-efficiency with minimal side effects.

Another key contributor to market growth is the availability of favorable government insurance policies and programs for patients with rare illnesses. In the U.S. and Europe, there are multiple government healthcare agencies, including the National Institutes of Health and the National Center for Advancing Translational Sciences (NCATS), that offer subsidized medications for rare diseases. Acromegaly is a Japanese incurable disease. The entire treatment cost can be covered by insurance. These initiatives will likely boost growth in the near future.

Regional Analysis:

North America was the country with the highest revenue share of 36% in 2021, due to its increasing prevalence and favorable government policies. A report from the U.S. Endocrine Society states that acromegaly prevalence was between 42 and 126 cases per thousand in 2021. The regional market will be boosted by the increased collaboration between major players in the development of new formulations and the assurance of high-quality products.

Asia Pacific will, however, be experiencing the fastest CAGR over the forecast period. In the near future, there will be remunerative growth opportunities due to the rising healthcare spending in countries like China and India. Sun Pharma and WOCKHARDT, for example, are currently developing new formulations of the octreotide molecule.

Кеу Regions and Countries covered іn thе rероrt:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Key Companies & Market share Analysis:

Markets are consolidated by large and small companies. It is led by players such as Novartis AG, Ipsen Pharma, and Pfizer Inc. In the past few years, many key contributors and new players have been added to the organization.

Companies are now focusing on the implementation of strategies such as new formulations, partnerships, distribution agreements, and regional expansion to increase revenue share. Novartis, for example, launched Signifor LAR to maintain its market share following the expiry of Sandostatin LAR’s patent. Chiasma Inc., which is currently in the clinical trial phase, is developing oral octreotide that is easier to administer. ISIS 766720, a clinical trial by Ionis Pharmaceuticals Inc., is currently in phase 2.

Key Market Players:

• Ipsen Pharma
• Novartis AG
• Pfizer Inc.
• Chiasma Inc.
• Validus Phermaceuticals LLC
• Sun Pharmaceutical Industries Ltd.
• WOCKHARDT
• Other Key Players

For the Acromegaly Treatment Market research study, the following years have been considered to estimate the market size: